User profiles for M. Hensley
Martee HensleyMemorial Sloan Kettering Verified email at mskcc.org Cited by 22296 |
[HTML][HTML] Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda
An unresolved issue in the field of implementation research is how to conceptualize and
evaluate successful implementation. This paper advances the concept of “implementation …
evaluate successful implementation. This paper advances the concept of “implementation …
Self‐management education and regular practitioner review for adults with asthma
…, P Haywood, A Bauman, MJ Hensley… - Cochrane database …, 1996 - cochranelibrary.com
Background A key component of many asthma management guidelines is the recommendation
for patient education and regular medical review. A number of controlled trials have …
for patient education and regular medical review. A number of controlled trials have …
Limited (information only) patient education programs for adults with asthma
…, H Powell, A Wilson, MJ Hensley… - Cochrane database …, 1996 - cochranelibrary.com
Background A key component of many asthma management guidelines is the recommendation
for patient education and regular medical review. A number of controlled trials have …
for patient education and regular medical review. A number of controlled trials have …
[HTML][HTML] Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation
Background Risk-reducing salpingo-oophorectomy is often considered by carriers of BRCA
mutations who have completed childbearing. However, there are limited data supporting the …
mutations who have completed childbearing. However, there are limited data supporting the …
[HTML][HTML] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
…, Z Rudzki, A Hochhaus, ML Hensley… - … England Journal of …, 2003 - Mass Medical Soc
Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We …
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We …
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
OBJECTIVE.: Recent studies have suggested that the definition of optimal cytoreduction for
advanced EOC should be changed from the current Gynecologic Oncology Group threshold …
advanced EOC should be changed from the current Gynecologic Oncology Group threshold …
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
ML Hensley, R Maki, E Venkatraman… - Journal of Clinical …, 2002 - ascopubs.org
… were enrolled onto a phase II study of gemcitabine 900 mg/m 2 intravenously (IV) on days
1 and 8 plus docetaxel 100 mg/m 2 IV on day 8 with granulocyte colony-stimulating factor …
1 and 8 plus docetaxel 100 mg/m 2 IV on day 8 with granulocyte colony-stimulating factor …
[PDF][PDF] Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma …
Purpose Gemcitabine as a single agent and the combination of gemcitabine and docetaxel
have activity in patients with metastatic soft tissue sarcoma. To determine if the addition of …
have activity in patients with metastatic soft tissue sarcoma. To determine if the addition of …
[HTML][HTML] Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase …
…, M Von Mehren, RL Jones, ML Hensley… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
… Patients were randomly assigned in a 2:1 ratio to receive either trabectedin at a starting
dose of 1.5 mg/m 2 as a 24-hour intravenous (IV) infusion or dacarbazine at a starting dose of …
dose of 1.5 mg/m 2 as a 24-hour intravenous (IV) infusion or dacarbazine at a starting dose of …
[PDF][PDF] American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants
ML Hensley, KL Hagerty, T Kewalramani… - Journal of clinical …, 2009 - kaim.or.kr
… Hensley et al … Hensley et al … Braaksma M, Levendag P: Tools for optimal tissue
sparing in concomitant chemoradiation of advanced head and neck cancer: Subcutaneous …
sparing in concomitant chemoradiation of advanced head and neck cancer: Subcutaneous …